BIOTREND - New Products for Neurosciences Research

1 comment

1. Focus Newsletter BIOTREND Chemicals AG January 2009

   About Dimebolin dihydrochloride (brand name Dimebon): Dimebon is a histamine H1 receptor antagonist that has been used clinically in Russia as antihistaminergic drug since 1983. Recently it has been shown to inhibit brain cell death in preclinical studies of Alzheimer’s disease and Huntington’s disease, making it a potential treatment for these and other neurodegenerative diseases. It appears to operate through multiple mechanisms of action, e.g. blocking the action of neurotoxic beta-amyloid proteins, inhibiting L-type calcium channels and modulating the action of AMPA and NMDA glutamate receptors.

   For further informations see www.biotrend.ch or http://www.biotrend.ch/download/NET_NeuroNewsletterD0109.pdf

   BIOTREND Chemicals AG was created in March 2007 in Wangen / Zurich by Gunther Jaeger (founder of Biotrend Chemikalien GmbH) and Werner Hassler (founder of ANAWA Trading SA and Biotrend Chemikalien GmbH). BIOTREND Chemicals AG was instigated in order to meet the growing demand from customers for an independent and technologically orientated distribution facility offering high quality, yet cost-effective products for biochemical, immunochemical and pharmaceutical research. Through our innovative strength we are not only providing our customers a vast product range, but also a high quality, first-class service package. At present we offer more than 1.500 products that have successfully been implemented not only in the drug discovery market, but also in cancer research as well as other scientific fields.

   Markus Kathmann, PhD
   BIOTREND Chemikalien GmbH
   Chief Scientific Officer (CSO)
   www.biotrend.com

   Comment by Markus Kathmann, PhD — 17. March 2009 @ 12:42

« Measure phosphorylation events of MCM2 and Histone H3    Hundreds of Antibodies Validated for IHC and ICC »